<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2759">
  <stage>Registered</stage>
  <submitdate>6/05/2010</submitdate>
  <approvaldate>6/05/2010</approvaldate>
  <nctid>NCT01120535</nctid>
  <trial_identification>
    <studytitle>Crux Biomedical Evaluation of the Crux Inferior Vena Cava Filter 4</studytitle>
    <scientifictitle>Crux Biomedical Evaluation of the Crux Inferior Vena Cava Filter System 4 (RETRIEVE 4)</scientifictitle>
    <utrn />
    <trialacronym>RETRIEVE 4</trialacronym>
    <secondaryid>Crux04</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Pulmonary Embolism</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Clotting disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - Inferior Vena Cava Filter

Experimental: Crux Vena Cava Filter System - Subjects at risk for Pulmonary Embolism


Treatment: devices: Inferior Vena Cava Filter
Inplant of filter in inferior vena cava.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Clinical Success - Clinical Success is a composite endpoint consisting of technical success with freedom from pulmonary embolism, filter migration and device related events requiring intervention.</outcome>
      <timepoint>6 Months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Rates of complications related to vena cava filter use.</outcome>
      <timepoint>6 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Patient has a permanent or temporary risk of Pulmonary Embolism.

          -  Patient must provide informed consent At least one of the following conditions -

          -  Proven PE

          -  Recurrent PE despite adequate

          -  Contraindication to anticoagulation

          -  Inability to achieve/maintain therapeutic anticoagulation

          -  Iliocaval DVT

          -  Large, free-floating proximal DVT

          -  Massive PE treated with thrombolysis/thrombectomy

          -  Chronic PE treated with thrombectomy

          -  Protection during thrombolysis for iliocaval DVT

          -  PE with limited cardiopulmonary reserve

          -  Poor compliance with anticoagulation medication

          -  High risk of injury worsening on anticoagulation

          -  Multi-trauma patient with high risk of PE

          -  Surgical patients at high risk of PE

          -  Medical condition with high risk of PE Patients with a documented vena cava diameter
             of 17-28mm Patient has IVC anatomy suitable for infra-renal placement Patient is
             willing to be available for the appropriate follow up</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Age &lt;18 years old

          -  Patient has any one of the following conditions:

               -  Renal vein thrombosis

               -  IVC thrombosis extending to the renal veins

               -  Duplicate IVC

               -  Gonadal vein thrombosis

               -  Requires supra-renal placement

          -  Vena cava diameter of 17-28mm

          -  Uncontrolled infectious disease

          -  Risk of aseptic PE

          -  Uncontrolled coagulopathy

          -  Existing inferior vena cava filter implant

          -  Life expectancy less than 6 months

          -  Pregnant or planning a pregnancy in the next 6 months

          -  Condition that inhibits radiographic visualization of the IVC

          -  Known allergy or intolerance to polytetrafluoroethylene (PTFE) or Nitinol

          -  Known hypersensitivity to contract which cannot be pretreated

          -  Access vessels preclude same insertion of delivery system

          -  Participation in another drug or device trial

          -  Unable or unwilling to cooperate with study procedures or required follow-up visits</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/05/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>20</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/01/2012</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Royal Brisbane Womens Hospital - Brisbane</hospital>
    <hospital>The Alfred Hospital - Melbourne</hospital>
    <postcode> - Brisbane</postcode>
    <postcode> - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Crux Biomedical</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine if the Crux Vena Cava Filter System is safe and
      effective in preventing pulmonary embolism.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01120535</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>